ACHV Strangle Strategy
ACHV (Achieve Life Sciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV (Achieve Life Sciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $317.2M, a beta of 2.25 versus the broader market, a 52-week range of 2-6.15, average daily share volume of 1.1M, a public-listing history dating back to 1995, approximately 25 full-time employees. These structural characteristics shape how ACHV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.25 indicates ACHV has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ACHV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ACHV snapshot
As of May 15, 2026, spot at $5.37, ATM IV 103.40%, IV rank 22.91%, expected move 29.64%. The strangle on ACHV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ACHV specifically: ACHV IV at 103.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ACHV strangle, with a market-implied 1-standard-deviation move of approximately 29.64% (roughly $1.59 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ACHV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ACHV should anchor to the underlying notional of $5.37 per share and to the trader's directional view on ACHV stock.
ACHV strangle setup
The ACHV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ACHV near $5.37, the first option leg uses a $5.64 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ACHV chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ACHV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.64 | N/A |
| Buy 1 | Put | $5.10 | N/A |
ACHV strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ACHV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ACHV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ACHV
Strangles on ACHV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ACHV chain.
ACHV thesis for this strangle
The market-implied 1-standard-deviation range for ACHV extends from approximately $3.78 on the downside to $6.96 on the upside. A ACHV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ACHV IV rank near 22.91% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ACHV at 103.40%. As a Healthcare name, ACHV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ACHV-specific events.
ACHV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ACHV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ACHV alongside the broader basket even when ACHV-specific fundamentals are unchanged. Always rebuild the position from current ACHV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ACHV?
- A strangle on ACHV is the strangle strategy applied to ACHV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ACHV stock trading near $5.37, the strikes shown on this page are snapped to the nearest listed ACHV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ACHV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ACHV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 103.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ACHV strangle?
- The breakeven for the ACHV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ACHV market-implied 1-standard-deviation expected move is approximately 29.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ACHV?
- Strangles on ACHV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ACHV chain.
- How does current ACHV implied volatility affect this strangle?
- ACHV ATM IV is at 103.40% with IV rank near 22.91%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.